KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old targetMarta Román, Ignacio Gil‐Bazo, Iosune Baraibar et al.|Molecular Cancer|2018Cited by 306
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Luis E. Raez, Ignacio Gil‐Bazo et al.|Expert Opinion on Investigational Drugs|2015Cited by 153
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, María José Serrano, Andrés F. Cardona et al.|Critical Reviews in Oncology/Hematology|2020Cited by 135
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cellsXiangnan Guan, Namrata S. Patil, Ruozhen Hu et al.|Nature|2024Cited by 121